MR spectroscopy in breast cancer: retrospective study of a population with high prevalence of disease Poster No.: C-2025 Congress: ECR 2015 Type: Scientific Exhibit Authors: D. De Falco Alfano 1, R. N. Abousiam 2, R. Duati 2, E. Cagnati 2, N. Keywords: DOI: Murri dello Diago 2, M. Giganti 2 ; 1 Cona/IT, 2 Ferrara/IT Cancer, Diagnostic procedure, MR-Spectroscopy, Breast 10.1594/ecr2015/C-2025 Any information contained in this pdf file is automatically generated from digital material submitted to EPOS by third parties in the form of scientific presentations. References to any names, marks, products, or services of third parties or hypertext links to thirdparty sites or information are provided solely as a convenience to you and do not in any way constitute or imply ECR's endorsement, sponsorship or recommendation of the third party, information, product or service. ECR is not responsible for the content of these pages and does not make any representations regarding the content or accuracy of material in this file. As per copyright regulations, any unauthorised use of the material or parts thereof as well as commercial reproduction or multiple distribution by any traditional or electronically based reproduction/publication method ist strictly prohibited. You agree to defend, indemnify, and hold ECR harmless from and against any and all claims, damages, costs, and expenses, including attorneys' fees, arising from or related to your use of these pages. Please note: Links to movies, ppt slideshows and any other multimedia files are not available in the pdf version of presentations. www.myesr.org Page 1 of 10
Aims and objectives Aim of the present study is to evaluate the correlation between histologic grading of breast carcinoma and presence of choline peak ( tcho) using MR spetroscopy sequence. Methods and materials 58 women (range 29-79 years) were retrospectively analyzed; suspected malignacy lesions were detected by mammography or ultrasound and than Magnetic Resonance Spectroscopy was performed in all patients (between February 2010 through April 2014). 60 lesions were analyzed, 20 of which were found at the histological examination as grade II, 20 as grade III and 20 grade I lesions. Non-continuous variables were considered, especially the variable grading and the tcho variable. The sensitivity of spectroscopic examination and its IC95 (confidence interval 95%) has been calculated and statistical analysis has been made to evaluate the relationship between Grading variables and tcho, in particular it has been used Pearson's Chi-square test (#²) and Fisher's exact test (considering significant P-value < 0.05). Images for this section: Page 2 of 10
Fig. 1: CUP Syndrome: small area of enhancement surrounded by area of non masslike enhancement to the passage of the lower quadrants of the left breast. They are also recognizable axillary lymph nodes that represent the clinical onset of the disease. Page 3 of 10
Fig. 2: Analysis of dynamic enhancement. Page 4 of 10
Fig. 3: Analysis of dynamic enhancement shows a type 2 (plateau) signal intensity time Page 5 of 10
Fig. 4: DWI sequence: the ADC value is compatible with the proliferative disease Page 6 of 10
Fig. 5: Sequence of proton spectroscopy demonstrates the presence of a significant peak of Choline Page 7 of 10
Results The sensitivity were 0.756 (76%). The histologic grade and the peak of choline showed a statistically significant relationship: # ² =6.592 p = 0.026 Fisher's exact test produced similar results to those obtained using the Chi-square test (# ²): F = 6.074 p = 0.038 Conclusion With the increase of the histological grading (Gold Standard) it has been seen an increase in percentage of choline peaks. Personal information Daniele De Falco Alfano Morphology, Surgery and Experimental Medicine Diagnostic Imaging Section Ferrara University Hospital 4, Aldo Moro Street 44122 Ferrara Italy mail:defalco.md@gmail.com References 1. Sivajaran U, Jayapragasam KJ, Ramhat et al: Dynamic contrastenhancement MRI evaluation of breast lesions- amorphological and quantitative analysis. J HK Coll Radiol 2009; 12:46-55 Page 8 of 10
2. Roebuck JR, Cecil KM, Shnall MD, Lenkinski RE; Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998, 209: 269-275 3. Jonathan KB Begley, Thomas W Redpath, PJ Bolan, Fiona Gilbert: in vivo proton magnetic resonance of breast cancer: a review of the literature. Breast Cancer research 2012, 14: 207 4. Baltzer PA, Dietzel M. Breast lesions: diagnosis by using proton MR- Spectroscopy at 1.5 T and 3T- systematic review and meta-analysis. Radiology, 2013 Mar 6. 5. Luigi Cei: Tecniche di Tomografia Computerizzata e Risonanza Magnetica, 2011. 6. Sylvia H Heywang Kobrunner, Astrid H, Stefan Sedlacek: Magnetic Resonance Imaging: The evolution of breast imaging. The Breast 22 (2013) S77-S8. 7. Manuale di diagnostica per immagini: per il corso di laurea in medicina e chirurgia / Pietro Torricelli, Stefano Mignani, Maurizio Zompatori ; coordinatore editoriale: Pietro Torricelli. - Bologna : Esculapio, 2008. - XIX, 697 p. : ill. ; 28 cm. 8. Breast. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 171-180. 9. Gianmario Mariuzzi: Anatomia patologica e correlazioni anatomo-cliniche (Vol. 2, 2006-2007). 10. Classificazione BI-RADS, 5 edizione, 2012. 11. Giorgio Cittadini, Giuseppe Cittadini, Francesco Sardanelli et al.: Diagnostica per immagini e radioterapia, 6 ed, Genova 2008. 12. Bolan PJ, Magnetic resonance spectroscopy of the breast: current status. Magn Reson Imaging Clin N Am. 2013 Nov 22. 13. Katz-Brull R, Serger D, Rivenson-Segal D, Arushkin E, Degan H: Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether phspholipide synthesis. Cancer Res 2002, 62: 1966-1970. 14. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M: in vivo quantification of choline compounds in the breast with 1 H-MR spectroscopy. Magn Res Med 2003, 50: 1134-1143. 15. Sardanelli F, Fausto A, Leo GD, Nijs RD, Vorbuchner M, Podo F: In vivo proton MR spectroscopy of the breast using the total coline peak integral as a marker of malignancy. Am J Roentgenol 2009, 192: 1608-1617. 16. Redpath TW: Signal-to-noise ratio in MRI. Br J Radiol 1998, 71: 704-707. 17. Bakken IJ, Gribbestad IS, Singstad TE et al. External standard metod for the in vivo quantification of choline containing compounds in breast tumors by proton MR spectroscopy at 1.5 T. Magn Reson Med 2001; 46(1): 189-92. 18. Tozaki M, Fukuma E. 1 H-MRS spectroscopy and diffusion weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy? AJR Am J Roentgenol 2009; 193(3): 840-9. 19. Hoult DI, Phil D. Sensitivity and power deposition in a high-field imaging experiment. J Magn Reson imaging 2000; 12(1): 46-47. Page 9 of 10
20. Vaughan JT, Garwood M, Collins CM, et al. 7T vs 4T: RF power, homogeneity, and signal to noise comparaison in head images. Magn Reson med 2001; 46(1): 24-30. 21. S. Suppiah, K. Rhamat et al: Improved diagnostic accuracy in differentiating malignant and benign lesions using single-voxel proton MRS of the breast at 3T. Clin Radiol 68(2013) e502-e510. 22. Kim JK, Park SH, Lee HM, et al. In vivo 1 H-MRS evaluation of malignant and benign breast diseases. Breast 2003: 12: 179-82. 23. Jeon-Hor Chen, Ming Hi Su: Clinical Application of Magnetic Resonance Imaging in Management of Breast Cancer Patients Receiving Neoadjuvant Chemoterapy. Hindawi Publishing Corporation. BioMed research International, vol. 2013, Article ID 348167, 14 pages. 24. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvantchemoterapy of locally advanced breast cancer: predicting response with in vivo 1 H-MR Spectroscopy- a pilot study at 4T. Radiology 2004; 233(2) 424-31. Page 10 of 10